Neglected tropical disease drug development
4 European H2020 organizations list this as part of their work — 2 as their primary capability.
Most active in this area
- UNIVERSITAETSKLINIKUM TUEBINGEN
German university hospital providing clinical trial sites and patient cohorts across pediatrics, stroke, rare diseases, infectious disease, and vaccine development in European consortia.
“TT4CL focuses on clinical development of oleylphosphocholine for cutaneous leishmaniasis treatment.”
DE7 projects - CELGENE MANAGEMENT SARL
Global pharma company contributing oncology expertise, real-world patient data, and drug development knowledge to large European health research consortia.
“Participated in HELP, a pan-nematode drug development platform targeting soil-transmitted helminthiasis and filariasis through Phase 1 trials.”
CH6 projects - TEHRAN UNIVERSITY OF MEDICAL SCIENCES
Iran's leading medical university contributing clinical research, drug development, and biosensor expertise to international health consortia.
“TT4CL project focuses on clinical development (preclinical through Phase I) of oral oleylphosphocholine for cutaneous leishmaniasis treatment.”
PrimaryIR3 projects - THE REGISTERED TRUSTEES OF THE IFAKARA HEALTH INSTITUTE
Tanzanian research institute providing clinical trial capacity and field expertise for infectious disease drug development and global health interventions.
“HELP project targets soil-transmitted helminthiasis, filariasis, and onchocerciasis with three drug candidates (Corallopyronin A, Oxantel pamoate, oxfendazol) through Phase 1 trials.”
PrimaryTZ3 projects